rifampicin

Ligand id: 2765

Name: rifampicin

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: rifampicin

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 12
Hydrogen bond donors 6
Rotatable bonds 5
Topological polar surface area 220.15
Molecular weight 822.41
XLogP 1.96
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used in the treatment of tuberculosis and related mycobacterial infections. This drug is approved by the US FDA using its USAN, rifampin. There is no information regarding approval for clinical use of this drug on the European Medicines Agency website. Individual national approval agencies may have granted marketing authorisation. For example, this drug has been approved in the UK since 2005.
Mechanism Of Action and Pharmacodynamic Effects
Inhibitis DNA-dependent RNA polymerase, leading to the suppression of RNA synthesis and cell death.
External links